Incyte extends hematology data at EHA, shares track NASDAQ biotech peers

By Christina Vogel, Background & Management desk. Reviewed prior to publication on 2026-06-25, 17:22.

Incyte (US45337C1027) continues to showcase late-stage hematology and oncology data from recent scientific meetings, including the EHA 2026 congress, as a NASDAQ-listed mid-cap biotech with a focus on myeloproliferative neoplasms and immuno-oncology. The company sits in the same global oncology peer group as Gilead Sciences and Bristol Myers Squibb, both listed in the S&P 500.

What recent data show

On June 14, 2026, Incyte reported new Phase 2 results for INCA033989 in myelofibrosis and essential thrombocythemia, highlighting rapid and sustained molecular responses and a favorable tolerability profile in these hematologic malignancies. According to a conference summary, the data were presented at the European Hematology Association (EHA) 2026 meeting and support further development in myelofibrosis, a chronic bone marrow cancer.

In a separate update in mid-June, Mirum Pharmaceuticals and Incyte disclosed positive pivotal Phase 2 data from the PROGRESS study of zilurgisertib in fibrodysplasia ossificans progressiva, a rare ultra-orphan disorder characterized by progressive heterotopic ossification. The partners reported clinically meaningful reductions in new heterotopic bone formation compared with placebo, supporting discussions with regulators on potential Phase 3 pathways and future registration strategies.

Valuation and NASDAQ context

Incyte shares are listed on NASDAQ under the ticker INCY, where the stock closed at 108.46 US dollars on June 24, 2026, according to MarketBeat. A TradingKey valuation snapshot shows a current price-to-earnings ratio of 14.87, placing the company at a moderate earnings multiple compared with a recent low of 12.64 and a very elevated historic high around 822.

On the same TradingKey analysis, Incyte’s valuation score stands at 8.72 on a sector-comparative scale, ranking the company 78 out of 157 firms in the broader Pharmaceuticals and Biotechnology group. MarketBeat notes that Incyte’s 50-day trading range has spanned roughly 92.24 to 109.10 dollars, framing the current level near the upper end of recent trading.

How Incyte makes its money

Incyte’s business model centers on developing and commercializing targeted therapies for oncology and inflammatory diseases, with a particular focus on small-molecule inhibitors and immunotherapies. A core revenue driver is ruxolitinib, marketed as Jakafi in the United States for myelofibrosis and polycythemia vera, where Incyte books U.S. sales while Novartis commercializes the drug ex-U.S. under a licensing arrangement.

Where the stock trades today

The Incyte shares (US45337C1027) most recently traded on NASDAQ at 108.46 US dollars as of 2026-06-24, 16:00 Eastern Time, according to MarketBeat.

This article is for informational purposes only and does not constitute investment advice, an offer or a solicitation to buy or sell any financial instrument. Investors should conduct their own research or consult a qualified adviser before making investment decisions.